PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients

被引：36
作者：
Abuchowski, A. [1 ]
机构：
[1] Prolong Pharmaceut, South Plainfield, NJ 07080 USA
来源：
OXYGEN TRANSPORT TO TISSUE XXXVII | 2016年 / 876卷
关键词：
SANGUINATE; Clinical; Safety; Hypoxia; Ischemia; CARBON-MONOXIDE; HEMOGLOBIN;
D O I：
10.1007/978-1-4939-3023-4_58
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Oxygen transfer agents have long been sought as a means to treat hypoxia caused by congenital or acquired conditions. Hemoglobin-based oxygen carriers were in clinical development as blood substitutes, but development was halted due to the finding of significant vasoactivity. Rather than develop a blood substitute, a product for indications characterized by hypoxia is in development. PEGylated bovine carboxyhemoglobin (SANGUINATE (TM)) is both a carbon monoxide releasing molecule and an oxygen transfer agent. It is comprised of three functional components that act to inhibit vasoconstriction, reduce inflammation and optimize the delivery of oxygen. SANGUINATE has the potential to reduce or prevent the effects of ischemia by inhibiting vasoconstriction and re-oxygenating tissue. Phase 1 safety trials in healthy volunteers were completed in 2013. SANGUINATE was shown to be safe and well tolerated with no serious adverse effects. Phase Ib studies have been completed in stable patients with Sickle Cell Disease. SANGUINATE has also been administered to two patients under emergency use protocols. Both patients exhibited improved status following treatment with SANGUINATE.
引用
收藏
页码：461 / 467
页数：7
相关论文
共 16 条
[1]  
Alaali Y, 2014, J SICKLE CELL HEMOGL, V1, P1
[2]   Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice [J].
Ananthakrishnan, Radha ;
Li, Qing ;
O'Shea, Karen M. ;
Quadri, Nosirudeen ;
Wang, Lingjie ;
Abuchowski, Abraham ;
Schmidt, Ann Marie ;
Ramasamy, Ravichandran .
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2013, 41 (06) :428-436
[3]   Examining and Mitigating Acellular Hemoglobin Vasoactivity [J].
Cabrales, Pedro .
ANTIOXIDANTS & REDOX SIGNALING, 2013, 18 (17) :2329-2341
[4]  
Carrol J, 2013, FIERCE BIOTECH
[5]   Use of carbon monoxide as a therapeutic agent: promises and challenges [J].
Foresti, Roberta ;
Bani-Hani, Mohamed G. ;
Motterlini, Roberto .
INTENSIVE CARE MEDICINE, 2008, 34 (04) :649-658
[6]   Early Treatment of Transient Focal Cerebral Ischemia with Bovine PEGylated Carboxy Hemoglobin Transfusion [J].
Klaus, Judith A. ;
Kibler, Kathleen K. ;
Abuchowski, Abraham ;
Koehler, Raymond C. .
ARTIFICIAL CELLS BLOOD SUBSTITUTES AND BIOTECHNOLOGY, 2010, 38 (05) :223-229
[7]   PEGylated Carboxyhemoglobin Bovine (SANGUINATE): Results of a Phase I Clinical Trial [J].
Misra, Hemant ;
Lickliter, Jason ;
Kazo, Friedericke ;
Abuchowski, Abraham .
ARTIFICIAL ORGANS, 2014, 38 (08) :702-707
[8]   Evaluation of MP4OX for Prevention of Perioperative Hypotension in Patients Undergoing Primary Hip Arthroplasty with Spinal Anesthesia A Randomized, Double-blind, Multicenter Study [J].
Olofsson, Christina I. ;
Gorecki, Andrzej Z. ;
Dirksen, Ris ;
Kofranek, Ivo ;
Majewski, Jacek A. ;
Mazurkiewicz, Tomasz ;
Jahoda, David ;
Fagrell, Bengt ;
Keipert, Peter E. ;
Hardiman, Yun J. ;
Levy, Howard .
ANESTHESIOLOGY, 2011, 114 (05) :1048-1063
[9]  
Parmar D, 2014, J SICKLE CELL HEMOGL, V1, P2
[10]   Characteristics of bovine hemoglobin as a potential source of hemoglobin-vesicles for an artificial oxygen carrier [J].
Sakai, H ;
Masada, Y ;
Takeoka, S ;
Tsuchida, E .
JOURNAL OF BIOCHEMISTRY, 2002, 131 (04) :611-617
12